Food and Drug Administration (FDA) 101

Similar documents
CDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA

FDA Nanotechnology Regulatory Science Program Science Board Presentation August 2010

Topics. Safety First Initiative. Drug Safety Communications DRUG SAFETY INITIATIVES AT THE FOOD AND DRUG ADMINISTRATION

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

US FDA: CMC Issues for INDs

KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar

Office for Human Subject Protection. University of Rochester

Baek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety

Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D

Defining Clinical Benefit in Clinical Trials: FDA Perspective

CANADA (HEALTH CANADA)

International Transfers of Personal Data at sanofi-aventis R & D

ACC February 2015 Quick Hit. FDA Hot Topics. David L. Rosen, B.S. Pharm., J.D. Foley & Lardner LLP (202)

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Center for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review.

The Drug Development Process and Design of Clinical Trials

INFORMATION ON JAPANESE REGULATORY AFFAIRS

FDA Update on Compounding

Glossary of Abbreviations

Health Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center

Protecting America s Health

Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE

From Molecules To Medicine

EU and FDA GMP Regulations: Overview and Comparison

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order

Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program

THE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE

FDA Oversight of Gene Therapy

FDA Advisory Committee Trends Since FDASIA

GMO Technology Conference

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

FDA > CDRH > CFR Title 21 Database Search

Combination Products Workshop: CGMP and PMSR Requirements. GMP by the Sea August 28, Mark D. Kramer Regulatory Strategies, Inc.

Role of USP Monographs and. General Chapters. Steve Zigler, Ph.D.

Guidance for Industry Postmarketing Studies and Clinical Trials Implementation of Section 505(o) of the Federal Food, Drug, and Cosmetic Act

USA Proprietary Name Review Process

Pharmacovigilance and the Generic Industry

Establishment of Clinical Trial Infrastructure

The Role of Chemists in the FDA Drug Approval Process

Global Clinical Trials in Korea

FDA Guidance, Clinical Pharmacology, and Regulatory Science

Regulatory Pathways for Rare Diseases

State Control of Medicines and Medical Devices in Russian Federation

CANADA (HEALTH CANADA)

Flexible and Pending Monographs

INFORMATION TECHNOLOGY

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA

CGMP and Postmarketing Safety Reporting Requirements for Combination Products

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

FDA approval of emergency expanded access use may be requested by telephone, facsimile, or other means of electronic communications.

The Future of Generic Pharmaceuticals

STIMULI TO THE REVISION PROCESS

Overview. A brief from

Replacing Analytical Methods for Release and Stability Testing CBER Perspective

Pharmaceutical Industry Research Credit Audit Guidelines

Under this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at

Cytochrome P450 Genotype Panel

Guidance for Industry Development and Use of Risk Minimization Action Plans

Regulatory Considerations and Trends Europe and the U.S.

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective

Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection

Comments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics

Globalization and the FDA The Alliance for a Stronger FDA Quarterly Member Meeting February 8, 2012

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Regulation of Microbiota- Based Products

Dr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority

Science & Research. Frequently Asked Questions. 1 of 6 7/8/ :52 PM

Mark D. Kramer, RAC Regulatory Strategies, Inc.

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015

Pharmaceutical Industry Research Credit Audit Guidelines - Revised - 4/30/04

Speed your time to market with FDA s expedited programs

PFF DISEASE EDUCATION WEBINAR SERIES. Welcome!

About Clinical Trials

Industry Perspective on Manufacturing in Early Development

Early Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical

IND Exemption, Preparation and Maintenance. Bruce K. Burnett, PhD, RAC (US, EU) Director, Regulatory Affairs Duke University

Advertising and Marketing Genetic Tests New Pathways or Old Roads?

Regulatory Affairs - CPS (RGA)

FDA Perspective on Plasma Quality and GMPs

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group

Rules of Human Experimentation

Pharmabiotics: a Regulatory Hurdle in Europe

Rebiotix: Business, Regulatory and Clinical Challenges in Commercializing a Microbiota Based Drug. May 2016

After approval, a biotechnology product continues to be subject to regulation

REGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts

A Regulators Perspective on U.S. Trade Policy Coordination

Food Beverage COMPLIANCE READINESS

Section I: Pharmaceuticals and Medical Devices

The Role of a Clinical Statistician in Drug Development By: Jackie Reisner

8. Clinical Trial Assessment Phase II

IVT Laboratory Week Jerry Lanese. Ph.D. The Lanese Group, Inc The Lanese Group, Inc.

ataluren overview A New Approach to Genetic Disorders

Volunteering for Clinical Trials

FDA. Design of Biomedical Devices and Systems, 2nd Edition, King & Fries, CRC Press, 2009.

Contact Information: Rapture Biotech D-201, Sector - 10, Noida Uttar Pradesh. Phone , ,

Transcription:

Food and Drug Administration (FDA) 101

What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the public health by: 1) Ensuring the safety and efficacy of human and veterinary drugs, biological products, medical devices 2) Ensuring the safety and security of our nation s food supply, products that emit radiation 3) Regulating the manufacture, marketing, and distribution of tobacco products. FDA also promotes the public health by striving to foster innovative approaches and solutions for some of our nation s most compelling health and medical challenges. 2

FDA Structure: Product Centers & Support Divisions Office of the Commissioner Provides leadership and direction Center for Drug Evaluation and Research Prescription, OTC drugs, and therapeutic biologics Center for Biologics Evaluation and Research Vaccines, blood, gene therapeutics Center for Devices and Radiological Health Medical devices and radiation-emitting products Office of Regulatory Affairs Conducts inspections, enforces FDA regulation National Center for Toxicological Research Supports Product Centers with technology, training, and technical expertise Center for Veterinary Medicine Feed, drugs, devices for animals Center for Food Safety and Applied Nutrition Foods other than meat and poultry, infant formulas, dietary supplements, cosmetics Center for Tobacco Products Tobacco products 4

Drugs and Biologics Regulation Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) REGULATES: Drugs, therapeutic biologics, some consumer products that are also considered drugs REGULATES: Blood, vaccines, and gene therapeutics 3

Drug Discovery & Development Overview: A Difficult Road Source: Drug Discovery and Development: Understanding the R&D Process. www.innovation.org 5

Drug Review and Approval Process: Clinical Testing Testing in humans to determine if the drug is safe and effective for the treatment of a disease TIMEFRAME: 6-7 Years Physicians carry out each trial working with patients in hospitals, offices and clinics, and coordinating closely with the sponsor company. Expensive and time-consuming, trials end more often in failure than success. PHASES: Phase 1 Clinical Trial: (20 to 100 healthy volunteers) Determine tolerability and initial safety in healthy volunteers, Pharmacokinetics. Phase 2 Clinical Trial: (100 to 500 patients) Study a drug s effectiveness; testing dose range and initial efficacy; define initial safety & tolerability profile in patients Phase 3 Clinical Trial: (1,000 to 5,000 patients) To confirm safety and efficacy. The longest and largest trials and often take place in hundreds of sites across the US and throughout the world. 9

Drug Review and Approval Process: Application to FDA If testing shows the medicine is safe and effective for the treatment, mitigation or prevention of a disease, the manufacturer submits the information to FDA for review and approval of a new medicine: THE APPLICATION CONTAINS: Clinical trial results demonstrating safety and efficacy Toxicology and Manufacturing information Proposed label- including effective uses, possible risks, and usage information For DRUGS it s called a New Drug Application (NDA) For Therapeutic BIOLOGICS it s a Biologics License Application (BLA) Both of these go to the Center for Drug Evaluation and Research CDER For most BIOLOGICS (VACCINES, BLOOD, and GENE THERAPEUTICS) applications are Biologics License Applications (BLA) They go to the Center for Biologics Evaluation and Research CBER 10

Drug Review and Approval Process: Review of Applications If a review by FDA physicians and scientists shows a drug's benefits outweigh its risks, and if the FDA feels that the drug can be manufactured in a way that ensure a quality product, the drug is approved and can be made available to doctors and patients in the United States. 11

Post-Market: Further Safety Monitoring FDA monitors and reviews additional data on a medicine such as adverse reactions or side effects found in clinical use or post-approval studies by the FDA. If a potential drug safety concern arises, a prompt review is conducted and the FDA's independent Drug Safety Oversight Board or an expert advisory committee may be consulted. POTENTIAL FDA ACTIONS INCLUDE: Revision to product labeling (e.g., add warnings) Require additional studies on an approved drug ( Phase 4 ) Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of a drug outweigh the risks; may include additional training, medication guide, patient package insert, or communication plan FDA Also works closely with the Centers for Disease Control and Prevention (CDC) to monitor adverse effects in VACCINES 13

Prescription Drug User Fee Act, 1992-2012 Two Decades of Success

Drug Review and Approval Process: Large Scale Manufacturing Going from small-scale to large-scale manufacturing is a major undertaking, often requiring construction of a new facility. Each facility is inspected by FDA and must meet strict guidelines for Good Manufacturing Practices (GMP) to ensure consistent identity, strength, and purity in production. FDA routinely inspects domestic and foreign plants for compliance with GMP and continues to do so throughout the medicine s life cycle. 12

Post-Market: Continued Oversight of Manufacturing and Distribution FDA CONTINUES TO MONITOR FOR QUALITY AND SAFETY: Active Ingredients Bulk Product Manufacturing Process & Conditions Packaging/Labeling Distribution chain POSTMARKET SURVEILLANCE AND ENFORCEMENT: Penalties for adulteration or misbranding include seizure, civil and criminal penalties, withdrawal of approval, and injunctions. 14

Drug Review and Approval Process: Pre-Discovery Understanding the disease Before any potential new medicine can be developed, scientists must work to understand the disease and its underlying causes. Researchers from government, academia and industry are typically involved. This stage often takes many years of work, and often leads to frustrating dead ends. Even successful research requires many years of work to develop a basic understanding of a disease s function into a new treatment. SCIENTISTS MUST UNDERSTAND: Underlying causes of the disease Physiological changes Best way to target the disease How the disease affects the patient The Pre-Discovery stage also includes: Target Identification: Choosing a biochemical process or specific molecule to target with a new medicine Target Validation: Testing the target and confirming its effect in modifying the disease 6

Drug Review and Approval Process: Drug Discovery Finding promising molecules that could become a new medicine Armed with their understanding of the disease, scientists are ready to begin looking for a molecule that may act on their target to alter the disease course. This is called a LEAD COMPOUND. If successful over long odds and years of testing, the lead compound can ultimately become a new medicine. SOURCES OF LEAD COMPOUNDS INCLUDE: Nature: found in bacteria, plants, etc. De Novo Synthesis: molecules designed in the laboratory High-throughput Screening: the most common way that leads are foundautomated testing of hundreds of thousands of compounds from a chemical library Biotechnology: genetically engineer living cells to produce disease-fighting biological molecules The Drug Discovery stage also includes: Early Safety and Toxicology Tests on promising compounds Lead Optimization, altering the structure of lead candidate to make it more suitable for use as a human medicine 7

Questions?

Thank You.